Hansoh Pharma Achieves Record Brand Value of RMB 27.388 Billion in 2022, Ranking Third Nationally in Healthcare Sector

China Economic Net Beijing, September 7th, by reporter Guo Wenpei. On September 5th, the China Brand Construction Promotion Association, China Appraisal Society, and Xinhua News Agency National Brand Project Office jointly released the "2022 China Brand Value Evaluation Information." The brand value of Hansoh Pharma, the operating entity of Hansoh Pharmaceutical Group Company Limited, reached 27.388 billion yuan, ranking 3rd in the "Pharmaceutical Health Group" in China, setting a new record high.

"Publication of China Brand Value Evaluation Information" has been ongoing for nine years, adhering to international and national standards while upholding the principles of "scientific, fair, open, and recognized." It has become an important initiative in establishing a brand value evaluation mechanism with Chinese characteristics, building positive energy for Chinese brands, and promoting Chinese brands globally. As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has deeply implemented a brand-strengthening enterprise strategy, continuously enhanced technological innovation and intellectual property protection, and achieved fruitful results in innovative R&D, quality management, market and services, and social responsibility. Its brand influence and value have been increasing year by year.

It is reported that Hansoh Pharma, with a patient-centered approach, focuses on major disease treatment areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmune diseases. The company has established four major R&D centers in Maryland (U.S.), Shanghai, Lianyungang, and Changzhou (China), successfully launching six innovative drugs, with over 25 innovative drug projects at various clinical stages currently undergoing more than 40 clinical trials. The continuous successful commercialization of innovative drugs has become the driving force for the company's growth. Driven by the dual-engine strategy of "in-house R&D + business development (BD)," Hansoh Pharma has deeply invested in cutting-edge new drug technology fields globally, building an innovation ecosystem while actively promoting its self-developed products into international markets to benefit patients worldwide. Additionally, the company has consistently ranked among the top 100 global pharmaceutical enterprises and within the top three best industrial enterprises in China’s pharmaceutical R&D product pipeline for many years, and was named one of the "Top Ten Outstanding Brands in Jiangsu Brand Building" in 2021.

Building a world-leading brand to drive high-quality enterprise development. Looking ahead, Hansoh Pharma stated that it will fully leverage its role as an industry leader to support the globalization, innovation, and development of China’s pharmaceutical industry, contributing to the advancement of Chinese brands on the global stage.